Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
BMJ Open. 2021 Mar 10;11(3):e044637. doi: 10.1136/bmjopen-2020-044637.
Current evidence supporting the utility of electromagnetic (EM)-guided method as the preferred technique for nasoenteral feeding tube placement is limited. We plan to provide a meta-analysis to compare the performance of EM-guided versus endoscopic placement.
Randomised controlled trials evaluating EM-guided versus endoscopic placement will be searched in MEDLINE, EMBASE and CENTRAL from database inception to 30 September 2020. Data on study design, participant characteristics, intervention details and outcomes will be extracted. Primary outcomes to be assessed are complications. Secondary outcomes include procedure success rate, total procedure time, patient recommendation, length of hospital stay and mortality. Study quality will be assessed using the Cochrane risk of bias tool. Data will be combined with a random effects model. The results will be presented as a risk ratio for dichotomous data and weighted mean difference for continuous data. Publication bias will be visualised using funnel plots. We will quantify the effect of potential effect modifiers by meta-regression if appropriate. The quality of evidence will be evaluated according to the Grading of Recommendations Assessment, Development and Evaluation framework.
This study will not use primary data, and therefore formal ethical approval is not required. The findings will be disseminated through peer-reviewed journals and committee conferences.
CRD42020172427.
目前支持电磁（EM）引导方法作为首选经鼻肠内喂养管放置技术的证据有限。我们计划进行一项荟萃分析，比较 EM 引导与内镜放置的性能。
我们将从数据库建立到 2020 年 9 月 30 日，在 MEDLINE、EMBASE 和 CENTRAL 中搜索评估 EM 引导与内镜放置的随机对照试验。将提取研究设计、参与者特征、干预措施细节和结果的数据。主要结局指标是并发症。次要结局包括程序成功率、总程序时间、患者推荐、住院时间和死亡率。使用 Cochrane 偏倚风险工具评估研究质量。将使用随机效应模型对数据进行合并。结果将以二分类数据的风险比和连续数据的加权均数差呈现。如果合适，将通过 meta 回归量化潜在效应修饰剂的影响。将根据推荐评估、制定和评估框架对证据质量进行评估。
本研究不会使用原始数据，因此不需要正式的伦理批准。研究结果将通过同行评审期刊和委员会会议传播。
PROSPERO 注册号：CRD42020172427。
